Page 245 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology ICU pharmacists and clinical outcomes

in the intensive care unit. JAMA. 1999;282(3):267-270. 35. Aghili M, Kasturirangan MN. Management of drug-drug
interactions among critically ill patients with chronic kidney
doi: 10.1001/jama.282.3.267
disease: Impact of clinical pharmacist’s interventions. Indian
26. Rivkin A, Yin H. Evaluation of the role of the critical care J Crit Care Med. 2021;25(11):1226-1231.
pharmacist in identifying and avoiding or minimizing
significant drug-drug interactions in medical intensive care doi: 10.5005/jp-journals-10071-23919
patients. J Crit Care. 2011;26(1):104.e1-e6. 36. Toukhy A, Fayed S, Sabry N, Shawki M. The impact of
an established pharmaceutical care pathway on drug
doi: 10.1016/j.jcrc.2010.04.014
related problems in an intensive care unit. Am J Med Sci.
27. Jiang SP, Zhu ZY, Ma KF, Zheng X, Lu XY. Impact of 2021;362(2):143-153.
pharmacist antimicrobial dosing adjustments in septic
patients on continuous renal replacement therapy in an doi: 10.1016/j.amjms.2021.03.007
intensive care unit. Scand J Infect Dis. 2013;45(12):891-899. 37. MacLaren R, Bond CA, Martin SJ, Fike D. Clinical and
doi: 10.3109/00365548.2013.827338 economic outcomes of involving pharmacists in the direct
care of critically ill patients with infections. Crit Care Med.
28. Jiang SP, Xu YY, Wu WF, et al. Improving antimicrobial 2008;36(12):3184-3189.
dosing in critically ill patients receiving continuous
venovenous hemofiltration and the effect of pharmacist doi: 10.1097/CCM.0b013e31818f2269
dosing adjustment. Eur J Intern Med. 2014;25(10):930-935. 38. Jiang SP, Zhu ZY, Wu XL, Lu XY, Zhang XG, Wu BH.
Effectiveness of pharmacist dosing adjustment for critically
doi: 10.1016/j.ejim.2014.08.001
ill patients receiving continuous renal replacement therapy:
29. Claus BO, Robays H, Decruyenaere J, Annemans L. A comparative study. Ther Clin Risk Manag. 2014;10:405-412.
Expected net benefit of clinical pharmacy in intensive care
medicine: A randomized interventional comparative trial doi: 10.2147/TCRM.S59187
with matched before-and-after groups. J Eval Clin Pract. 39. Dilokpattanamongkol P, Tangsujaritvijit V, Suansanae T,
2014;20(6):1172-1179. Suthisisang C. Impact of pharmaceutical care on pain and
doi: 10.1111/jep.12289 agitation in a medical intensive care unit in Thailand. Int J
Clin Pharm. 2017;39:573-581.
30. Oxman DA, Adams CD, Deluke G, et al. Improving
antibiotic de-escalation in suspected ventilator-associated doi: 10.1007/s11096-017-0456-0
pneumonia: An observational study with a pharmacist- 40. Mohammad RA, Eze C, Marshall VD, et al. The impact of
driven intervention. J Pharm Pract. 2015;28(5):457-461. a clinical pharmacist in an interprofessional intensive care
unit recovery clinic providing care to intensive care unit
doi: 10.1177/0897190014527316
survivors. J Am Coll Clin Pharm. 2022;5(10):1027-1038.
31. Hammond DA, Killingsworth CA, Painter JT, et al. Impact
of targeted educational interventions on appropriateness of doi: 10.1002/jac5.1671
stress ulcer prophylaxis in critically ill adults. Pharm Pract 41. Donovan AL, Aldrich JM, Gross AK, et al. Interprofessional
(Granada). 2017;15(3):948. care and teamwork in the ICU. Crit Care Med. 2018;
doi: 10.18549/pharmpract.2017.03.948 46(6):980-990.
32. Li Z, Cheng B, Zhang K, et al. Pharmacist-driven doi: 10.1097/CCM.0000000000003067
antimicrobial stewardship in intensive care units in East 42. Devlin JW, McKenzie C. Expanding the reach of critical care
China: A multicenter prospective cohort study. Am J Infect pharmacists globally. Crit Care Med. 2018;46(2):328-330.
Control. 2017;45(9):983-989.
doi: 10.1097/CCM.0000000000002879
doi: 10.1016/j.ajic.2017.02.021
43. Donchin Y, Gopher D, Olin M, et al. A look into the nature
33. Louzon P, Jennings H, Ali M, Kraisinger M. Impact of and causes of human errors in the intensive care unit. 1995.
pharmacist management of pain, agitation, and delirium Qual Saf Health Care. 2003;12(2):143-147; discussion 147-8.
in the intensive care unit through participation in
multidisciplinary bundle rounds. Am J Health Syst Pharm. doi: 10.1136/qhc.12.2.143
2017;74(4):253-262. 44. Brinkman S, Abu-Hanna A, De Jonge E, De Keizer NF.
Prediction of long-term mortality in ICU patients: Model
doi: 10.2146/ajhp150942
validation and assessing the effect of using in-hospital versus
34. Gu H, Sun L, Sheng B, Gu X, Wang S, Chen W. Effect long-term mortality on benchmarking. Intensive Care Med.
of Critical Care Pharmacist on Antibiotic Medication 2013;39(11):1925-1931.
Optimizations, Reduce Drug Costs But not Increase Mortality:
A Retrospective Cohort Study in the Real World Research. doi: 10.1007/s00134-013-3042-5
United States: Research Square; 2020. 45. Michalets E, Creger J, Shillinglaw WR. Outcomes of

Volume 9 Issue 3 (2025) 237 doi: 10.36922/EJMO025150116